CN102786574A - Glycyrrhetinic acid crystal A substance, its preparation method, and its applications in medicines and healthcare products - Google Patents
Glycyrrhetinic acid crystal A substance, its preparation method, and its applications in medicines and healthcare products Download PDFInfo
- Publication number
- CN102786574A CN102786574A CN201110127190XA CN201110127190A CN102786574A CN 102786574 A CN102786574 A CN 102786574A CN 201110127190X A CN201110127190X A CN 201110127190XA CN 201110127190 A CN201110127190 A CN 201110127190A CN 102786574 A CN102786574 A CN 102786574A
- Authority
- CN
- China
- Prior art keywords
- glycyrrhetinic acid
- crystal type
- acid crystal
- preparation
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 title claims abstract description 289
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 title claims abstract description 145
- 229960003720 enoxolone Drugs 0.000 title claims abstract description 145
- 239000013078 crystal Substances 0.000 title claims abstract description 110
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 239000000126 substance Substances 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 title claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 239000000463 material Substances 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 4
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 229960000935 dehydrated alcohol Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 21
- 239000000047 product Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 12
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 230000003203 everyday effect Effects 0.000 description 9
- 238000011160 research Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- -1 glycyrrhetinic acid ester Chemical class 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000005464 sample preparation method Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- FTQDJVZNPJRVPG-XWEVEMRCSA-N Acetoxolone Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)C)C1(C)C FTQDJVZNPJRVPG-XWEVEMRCSA-N 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229960004871 acetoxolone Drugs 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 208000037903 inflammatory enteropathy Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- MPDGHEJMBKOTSU-WFJWTYAKSA-N (2s,4as,6as,6br,10s,12as)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid Chemical compound C12C(=O)C=C3C4C[C@@](C)(C(O)=O)CC[C@]4(C)CC[C@@]3(C)[C@]1(C)CCC1[C@]2(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-WFJWTYAKSA-N 0.000 description 1
- MPDGHEJMBKOTSU-AWOGJAJBSA-N CC(C)(C(CC[C@@]1(C)[C@](C)(CC[C@@](C)(CC2)[C@H]3C[C@@]2(C)C(O)=O)C3=C2)[C@](C)(CC3)[C@H]1C2=O)[C@H]3O Chemical compound CC(C)(C(CC[C@@]1(C)[C@](C)(CC[C@@](C)(CC2)[C@H]3C[C@@]2(C)C(O)=O)C3=C2)[C@](C)(CC3)[C@H]1C2=O)[C@H]3O MPDGHEJMBKOTSU-AWOGJAJBSA-N 0.000 description 1
- 244000207740 Lemna minor Species 0.000 description 1
- 235000006439 Lemna minor Nutrition 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 235000001855 Portulaca oleracea Nutrition 0.000 description 1
- 241001415846 Procellariidae Species 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 238000005815 base catalysis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000001965 diffuse reflectance infrared spectroscopy Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
Images
Landscapes
- Steroid Compounds (AREA)
Abstract
本发明公开了式(I)所示的甘草次酸的一种新晶A型物质状态；甘草次酸晶A型样品的制备方法；以甘草次酸晶A型物质作为活性成分制备的产品，所述产品包括药品和保健品，以及甘草次酸晶A型防治疾病和保健中的应用。 The invention discloses a new crystal type A substance state of glycyrrhetinic acid represented by formula (I); a preparation method of a sample of glycyrrhetinic acid crystal type A; a product prepared by using glycyrrhetinic acid crystal type A substance as an active ingredient, The products include medicines and health care products, and the application of glycyrrhetinic acid crystal type A in disease prevention and health care.
Description
Technical field
The present invention relates to a kind of new crystal type A state of matter of glycyrrhetinic acid, the preparation method of glycyrrhetinic acid crystal type A sample adopts the product of glycyrrhetinic acid crystal type A material as activeconstituents, and the purposes of glycyrrhetinic acid crystal type A, belongs to medical technical field.
Background technology
Glycyrrhetinic acid, English Glycyrrhetinic acid by name, molecular structure is suc as formula shown in (I)
In Chinese patent CN101899081A (publication number), put down in writing " the glycyrrhetinic acid ester derivative compound method and the deoxidation glycyrrhetinic acid ester cpds " of inventions such as Zhang Aiming
[1], wherein related to the preparation method of the ester derivative of glycyrrhetinic acid.Do not relate to the glycyrrhetinic acid compound.
In Chinese patent CN1563073 (publication number), put down in writing " preparation method of glycyrrhetinic acid " of inventions such as Fan Yunge
[2], wherein relating to the glycyrrhizic acid inclusion compound is raw material, uses Potenlini to obtain the preparation method of glycyrrhetinic acid through acidolysis.It is different with the preparation method of present patent application that this patent belongs to the glycyrrhetinic acid compounds process for production thereof.
In Chinese patent CN1846705 (publication number), put down in writing " application in preparation treatment inflammatory bowel medicine of Potenlini or glycyrrhetinic acid " of Wuhan University's fourth rainbow invention
[3], wherein relate to the application in preparation inflammatory enteropathy medicine of Potenlini or glycyrrhetinic acid.Belong to the clinical application of glycyrrhetinic acid, do not relate to the glycyrrhetinic acid crystal formation and prepare problem.
In Chinese patent CN101254308 (publication number), put down in writing " glycyrrhetinic acid-polyoxyethylene glycol/chitosan liver target composite drug administration system and the preparation method " of inventions such as Yuan Zhi
[4], wherein relate to a kind of novel hepatic targeting drug carrier-glycyrrhetinic acid-polyoxyethylene glycol/chitosan or chitosan derivatives liver target composite drug administration system.Patent relates to the mixture preparation method with glycyrrhetinic acid, does not relate to the glycyrrhetinic acid crystal formation and prepares problem.
In Chinese patent CN101292952 (publication number), put down in writing " Potenlini, glycyrrhetinic acid or its salt or derivatives thereof thermo-sensitive gel and the method for making and the application " of inventions such as Ding Hong
[5], wherein related to Potenlini, glycyrrhetinic acid or its salt or derivatives thereof thermo-sensitive gel.Patent relates to glycyrrhetinic acid mixture preparation method, and the crystal formation that does not relate to glycyrrhetinic acid prepares problem.
In Chinese patent CN101919870A (publication number), put down in writing " glycyrrhetinic acid, the application of Potenlini in preparation prevention or treatment pulmonary fibrosis medicine " of inventions such as Zhang Lurong
[6], wherein relate to glycyrrhetinic acid, the application of Potenlini in preparation prevention or treatment pulmonary fibrosis medicine.Belong to the clinical application of glycyrrhetinic acid, do not relate to the glycyrrhetinic acid crystal formation and prepare problem.
In Chinese patent CN101920017A (publication number), put down in writing the inventions such as Wang Qing of Dalian University of Technology " being used to promote the compsn of glycyrrhetinic acid to realize percutaneous permeation "
[7], wherein related to a kind of compsn that is used to promote glycyrrhetinic acid to realize percutaneous permeation, belong to field of medicaments, patent relates to glycyrrhetinic acid mixture preparation method, and the crystal formation that does not relate to glycyrrhetinic acid prepares problem.
In Chinese patent CN101926815A (publication number), put down in writing inventions such as Zhou Haibin " a kind of peoniflorin and glycyrrhetinic acid composition and preparation method thereof and application "
[8], wherein related to peoniflorin and glycyrrhetinic acid composition.Patent relates to glycyrrhetinic acid mixture preparation method, and the crystal formation that does not relate to glycyrrhetinic acid prepares problem.
In Chinese patent CN101838303A (publication number), put down in writing " preparation method of glycyrrhetinic acid " of the inventions such as Pan Xuejun of Kunming University of Science and Technology
[9], wherein related to the process for purification of glycyrrhetinic acid.Wherein related to and utilized microwave technology to prepare the glycyrrhetinic acid method, the crystal formation that does not relate to glycyrrhetinic acid prepares problem.
In Chinese patent CN101817867A (publication number), put down in writing " a kind of preparation method of glycyrrhetinic acid " of inventions such as Gao Ying
[10], wherein related to the purification process of glycyrrhetinic acid, be about to Potenlini acid powder through extracting with organic solvent dissolution, concentrate and obtain extract, in acetic acid, obtain the acetyl glycyrrhetinic acid with ore deposit acid-catalyzed hydrolysis and acetylize; In the acetyl glycyrrhetinic acid, add entry or alcohol then, hydrolysis obtains thick glycyrrhetinic acid under base catalysis, adds the gac reflux decolour, and crystallization obtains glycyrrhetinic acid.The glycyrrhetinic acid inorganic salt that this method relates to are removed and decoloring method, and are different with the crystal formation preparation method of present patent application.
Through patent and literature search both at home and abroad, find progress relevant for glycyrrhetinic acid
[11,12], extraction process
[13], detection method
[14]And formulation
[15,16,17]Bibliographical information, but do not find the research of the relevant crystal formation of relevant glycyrrhetinic acid and crystal formation patent or bibliographical information.
It is different with above-mentioned patent or literature research report content that the present invention has found, is discovery, specimen preparation and the purposes of glycyrrhetinic acid new crystal material.Research purpose of the present invention is to start with from the research of glycyrrhetinic acid crystal formation solid matter; Through crystal formation triage techniques, crystal formation evaluated biological activity technology; The advantage crystal-form substances state that on identical active substance different crystal forms state aspect, seek, find, exploitation has the glycyrrhetinic acid of optimal clinical curative effect and healthcare products effect is for application country or international intellecture property invention patent protection provide science data from glycyrrhetinic acid crystal-form substances basis.
Summary of the invention
The technical problem that the present invention will solve provides a kind of new crystal formation of the glycyrrhetinic acid shown in the formula (I), i.e. crystal type A
Another technical problem that the present invention will solve provides the preparation method of glycyrrhetinic acid crystal type A material.
Another technical problem that the present invention will solve provides the product of glycyrrhetinic acid crystal type A composition as activeconstituents.
Another technical problem that the present invention will solve provides the application of glycyrrhetinic acid crystal type A.
Particularly, the technical problem for solving, adopt following technical scheme:
1. the crystal type A sample morphological specificity of glycyrrhetinic acid:
1.1 the glycyrrhetinic acid crystal type A solid substance, (CuK when using powder x-ray diffraction analysis
αRadiation), show as the Height%=100 peak position 2-Theta=15.0 ° ± 0.2 ° or
The place, exist 35 its positions of diffraction peak respectively 2-Theta (°) ± 0.2 ° of value or
Value has following expression:
And diffraction peak relative intensity value allows Height% ± 10% variation range (Fig. 1).
1.2 glycyrrhetinic acid crystal type A solid substance, its infrared absorption spectrum (Fig. 2) 3434,2946,2925,2860,2600,2095,1701,1663,1619,1541,1455,1429,1384,1367,1343,1324,1307,1282,1262,1220,1213,1200,1176,1154,1130,1101,1087,1076,1025,986,959,947,934,916,894,878,867,852,830,818,792,770,756,726,713,699,672cm
-1± 2cm
-1Absorption peak be the diffuse reflectance infrared spectroscopy peak position that the glycyrrhetinic acid crystal type A solid substance is appeared.
1.3 the glycyrrhetinic acid crystal type A solid substance contains one 300 ℃ ± 3 ℃ Peak endotherm(ic)peak position when temperature rise rate is 10 ℃ of PMs in its DSC collection of illustrative plates (Fig. 3).
1.4 glycyrrhetinic acid crystal type A solid substance, its melting point values are 296 ℃ ± 2 ℃.
2. the preparation method characteristic of glycyrrhetinic acid crystal type A sample:
2.1 the invention provides a kind of preparation method of glycyrrhetinic acid crystal type A sample, the glycyrrhetinic acid crystal type A solid sample that it is characterized in that using earlier THF, acetone, Virahol, methylene dichloride, ETHYLE ACETATE, propyl carbinol single solvent under normal temperature or high temperature, the glycyrrhetinic acid sample to be dissolved fully and directly or indirectly prepare through 4 ℃～80 ℃ of envrionment temperatures, ambient moisture 10%～75%, normal pressure or vacuum pressure condition.
2.2 the invention provides the preparation method of other a kind of glycyrrhetinic acid crystal type A sample, the glycyrrhetinic acid crystal type A solid sample that it is characterized in that using earlier any mixed solvent system that two or more are processed through different proportionings combinations in THF, acetone, 95% ethanol, absolute ethyl alcohol, Virahol, methylene dichloride, ETHYLE ACETATE, propyl carbinol, normal hexane, hexanaphthene, the water different sorts solvent under normal temperature or high temperature, the glycyrrhetinic acid sample to be dissolved fully and directly or indirectly prepare through 4 ℃～80 ℃ of envrionment temperatures, ambient moisture 10%～75%, normal pressure or vacuum pressure condition.
3. the crystal type A of glycyrrhetinic acid is as the using dosage and the purposes characteristic of active substance:
3.1 of the present invention a kind of product is provided also, with glycyrrhetinic acid crystal type A composition as activeconstituents and contain other auxiliary materials.Product of the present invention comprises medicine, healthcare products.
The crystal formation purity of glycyrrhetinic acid crystal type A is 1%～100% in the described product.
The formulation of said product is selected from tablet, capsule, pill, injection, slowly-releasing or control-released agent, pulvis.
Used the various products of glycyrrhetinic acid crystal type A material 3.2 the invention provides, comprised medicine, healthcare products, it is characterized in that the glycyrrhetinic acid crystal type A absorbs dosage in 1mg～40g scope its every day as the activeconstituents exploitation.
The various products of glycyrrhetinic acid crystal type A material have been used 3.3 the invention provides as the activeconstituents exploitation; Comprise medicine, healthcare products; It is characterized in that, used glycyrrhetinic acid crystal type A composition to guarantee its in vivo absorption characteristic, effectively bioavailability, effective blood drug concentration, stable time that continues and reach prevention, treatment, health-care effect and the application of making the most of the advantage as active substance.
4. glycyrrhetinic acid crystal type A oral administration absorbs characteristic:
The invention provides and use the various products of glycyrrhetinic acid crystal type A material as the activeconstituents exploitation; Comprise medicine, healthcare products; And the bio-absorbable effect after the oral administration, it is characterized in that glycyrrhetinic acid crystal type A material can reach peak concentration value, the active function characteristic in 12 hours maintenance platform cycles at 15 minutes quick actings, 1 hour blood through gi tract as activeconstituents.Fig. 4 provides the rat plasma concentration curve after the administration of glycyrrhetinic acid crystal type A sample oral administration.
5. the application of glycyrrhetinic acid crystal type A in pharmacy.
The invention provides the application of glycyrrhetinic acid crystal type A in the medicine of preparation treatment bronzed disease, inflammatory enteropathy and prevention or treatment pulmonary fibrosis.
Description of drawings
The x-ray diffractogram of powder spectrum of Fig. 1 glycyrrhetinic acid crystal type A sample
The infrared absorpting light spectra of Fig. 2 glycyrrhetinic acid crystal type A sample
The DSC collection of illustrative plates of Fig. 3 glycyrrhetinic acid crystal type A sample
Rat plasma concentration curve after the administration of Fig. 4 glycyrrhetinic acid crystal type A sample oral administration
Embodiment
Be better explanation technical scheme of the present invention, the spy provides following examples, but the present invention is not limited to this.
The direct preparation method of glycyrrhetinic acid crystal type A sample:
The crystal type A sample preparation methods of glycyrrhetinic acid; Step is to use the 20ml isopropanol solvent, and to be placed on temperature be under 40 ℃ the vacuum condition solvent to be drained under 30 ℃ of bath temperature conditions 290mg glycyrrhetinic acid sample being dissolved fully, prepares the glycyrrhetinic acid crystal form samples.
The x-ray diffractogram of powder spectrum of gained glycyrrhetinic acid crystal form samples is shown in accompanying drawing 1
The infrared absorpting light spectra of gained glycyrrhetinic acid crystal form samples is shown in accompanying drawing 2
The DSC collection of illustrative plates of gained glycyrrhetinic acid crystal form samples is shown in accompanying drawing 3
Above spectrum data result shows that present embodiment gained crystalline crystal formation is the glycyrrhetinic acid crystal type A.
The direct preparation method of glycyrrhetinic acid crystal type A sample:
The crystal type A sample preparation methods of glycyrrhetinic acid, step are to use the 20ml acetone solvent that sample is dissolved back adding normal hexane fully and produce throw out behind vacuum filtration, prepare the glycyrrhetinic acid crystal form samples.
The x-ray diffractogram of powder spectrum of gained glycyrrhetinic acid crystal form samples is shown in accompanying drawing 1
The infrared absorpting light spectra of gained glycyrrhetinic acid crystal form samples is shown in accompanying drawing 2
The DSC collection of illustrative plates of gained glycyrrhetinic acid crystal form samples is shown in accompanying drawing 3
Above spectrum data result shows that present embodiment gained crystalline crystal formation is the glycyrrhetinic acid crystal type A.
(commentaries on classics is brilliant) indirectly preparation method of glycyrrhetinic acid crystal type A sample:
The crystal type A sample preparation methods of glycyrrhetinic acid, step are that glycyrrhetinic acid crystal B-type sample after 24 hours, can be passed through rotating crystal method through 120 ℃ of high temperature, prepare the glycyrrhetinic acid crystal form samples.
The x-ray diffractogram of powder spectrum of gained glycyrrhetinic acid crystal form samples is shown in accompanying drawing 1
The infrared absorpting light spectra of gained glycyrrhetinic acid crystal form samples is shown in accompanying drawing 2
The DSC collection of illustrative plates of gained glycyrrhetinic acid crystal form samples is shown in accompanying drawing 3
Above spectrum data result shows that present embodiment gained crystalline crystal formation is the glycyrrhetinic acid crystal type A.
The problem that needs explanation: have 6 kinds owing to can be used for preparing the single organic solvent of crystal formation glycyrrhetinic acid sample; Mixed solvent has 11 kinds, every kind organic solvent boiling point value different, different to glycyrrhetinic acid sample dissolution degree, variate-values such as the envrionment temperature of its experiment, humidity, time all there is some difference property and constant interval scope when causing under using different solvents condition preparation crystal formation glycyrrhetinic acid sample.
The glycyrrhetinic acid crystal type A absorbs characteristic and Plasma Concentration characteristic in the rat body:
Adopt the conventional raising condition of SD rat of body weight 230 ± 5g to raise, freely drink water, behind the fasting 12h, give medicine, before administration, reach after the administration 0.083,0.25,0.5,1,1.5,2,3,4,6,8,12,24 (h) by 200mg/kg filling stomach.Eye socket is got the about 0.4ml of blood, and 4, the centrifugal 15min of 000rpm, preparation blood plasma.Get 150 μ l blood plasma, add methyl alcohol 200 μ l, vortex oscillation 1min, 13, the centrifugal 15min of 400rpm draws supernatant through 0.45 μ m filtering with microporous membrane, gets 20 μ l and carries out HPLC detection, Aligent XDB-C
18(150 * 4.6mm, 5 μ m), moving phase: methyl alcohol: 0.4% aqueous acetic acid=90: 10, flow velocity: 1ml/min detects wavelength: 254nm.The result can detect glycyrrhetinic acid in the blood after showing oral glycyrrhetinic acid crystal type A solid material, and reaches peak concentration value, the active function characteristic in 12 hours maintenance platform cycles through gi tract at 15 minutes quick actings, 1 hour blood.
Glycyrrhetinic acid crystal type A Plasma Concentration data
Embodiment 5
Glycyrrhetinic acid crystal type A sample is as the dosage of active constituents of medicine:
The medicinal tablet or other preparations that use crystal type A glycyrrhetinic acid material to manufacture as active constituents of medicine; It is characterized in that containing the activeconstituents of glycyrrhetinic acid crystal type A as medicine; Every day, dosage was 300mg; Can be prepared into 3 times/each 1 100mg conventional tablet every day respectively, every day 2 times/each 1 150mg conventional tablet or every day 1 time/each 1 300mg the tablet type.
The problem that needs explanation: the glycyrrhetinic acid crystal formation pharmaceutical composition that the present invention relates to has many factor affecting on the dosage of effective constituent, for example: be used to prevent different with the purposes of treating and cause the difference of dosage every day; Ill character is different with ill severity and cause the different of dosage every day; The difference of patient's sex, age, body surface area, route of administration, administration number of times, therapeutic purpose are different and cause the difference of dosage every day; In addition, absorption that exists between crystal form samples and Plasma Concentration are not equal, also cause the present invention to be the 0.01-150mg/kg body weight in appropriate dose scope every day of using glycyrrhetinic acid crystal type A composition, are preferably the 1-100mg/kg body weight.Should formulate different glycyrrhetinic acid crystal type A effective constituent total dose schemes with treatment different situations demand according to the prevention of reality during use, and can be divided into the single or multiple administering mode.
Glycyrrhetinic acid crystal type A sample is as the healthcare products dosage of active constituents of medicine:
Use crystal type A glycyrrhetinic acid material as the functional health product that activeconstituents manufactures, it is characterized in that containing in the healthcare products glycyrrhetinic acid crystal type A as the health active component substances, its consumption is from 1mg～40g.
Reference
1. Chinese patent, publication number CN101899081A
2. Chinese patent, publication number CN1563073
3. Chinese patent, publication number CN1846705
4. Chinese patent, publication number CN101254308
5. Chinese patent, publication number CN101292952
6. Chinese patent, publication number CN101919870A
7. Chinese patent, publication number CN101920017A
8. Chinese patent, publication number CN101926815A
9. Chinese patent, publication number CN101838303A
10. Chinese patent, publication number CN101817867A
The honor 11. pass away, Zhao Jie etc.The research of glycyrrhetinic acid and prospect.University Of Dalian's journal, 2005,26 (4): 85-88
12. surplus side, Gao Jianpei etc.From Radix Glycyrrhizae, extract the progress that Potenlini prepares glycyrrhetinic acid.Jiangxi agricultural journal, 2008,20 (8): 91-94
13. once opened China.From Radix Glycyrrhizae, extract the technical study of Potenlini and glycyrrhetinic acid.2006，8(1)：62-64
14. the refined duckweed of king, Cao Bo etc.Glycyrrhetinic acid method for measurement of concentration research in the rat plasma.People's Armed Police medical college journal, 2008,17 (3): 201-203
15. Zhu Ling, square petrel etc.The preparation of glycyrrhetinic acid emulsifiable paste and lipolysis research.Modern food science and technology, 2009,25 (11): 1335-1337
16. Wang Jun, Zhang Jian etc.The preparation of glycyrrhetinic acid polylactic acid microsphere and property research thereof.The time precious traditional Chinese medical science traditional Chinese medicines, 2009,20 (4): 1002-1003
17. Guo Bo is red, Cheng Yi etc.The preparation of glycyrrhetinic acid liposome and pharmaceutics Study on Properties thereof.Herbal medicine, 2010,41 (3): 380-383
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110127190XA CN102786574A (en) | 2011-05-17 | 2011-05-17 | Glycyrrhetinic acid crystal A substance, its preparation method, and its applications in medicines and healthcare products |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110127190XA CN102786574A (en) | 2011-05-17 | 2011-05-17 | Glycyrrhetinic acid crystal A substance, its preparation method, and its applications in medicines and healthcare products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102786574A true CN102786574A (en) | 2012-11-21 |
Family
ID=47152179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110127190XA Pending CN102786574A (en) | 2011-05-17 | 2011-05-17 | Glycyrrhetinic acid crystal A substance, its preparation method, and its applications in medicines and healthcare products |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102786574A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106543261A (en) * | 2016-10-27 | 2017-03-29 | 深圳市新阳唯康科技有限公司 | A kind of enoxolone crystal-form substances and preparation method thereof |
| CN106632575A (en) * | 2016-12-20 | 2017-05-10 | 深圳市新阳唯康科技有限公司 | Novel glycyrrhetinic acid crystal form and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3262851A (en) * | 1958-06-26 | 1966-07-26 | Biorex Laboratories Ltd | Pharmacological compositions containing glycyrrhetinic acid derivative |
| CN1563073A (en) * | 2004-04-06 | 2005-01-12 | 南开大学 | Method for preparing enoxolone |
| CN101607980A (en) * | 2009-06-15 | 2009-12-23 | 北京九草堂药物研究院有限公司 | A kind of preparation of licorice extract of bulk drug for livestock |
| CN101838303A (en) * | 2010-06-07 | 2010-09-22 | 昆明理工大学 | Preparation method of glycyrrhetinic acid |
-
2011
- 2011-05-17 CN CN201110127190XA patent/CN102786574A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3262851A (en) * | 1958-06-26 | 1966-07-26 | Biorex Laboratories Ltd | Pharmacological compositions containing glycyrrhetinic acid derivative |
| CN1563073A (en) * | 2004-04-06 | 2005-01-12 | 南开大学 | Method for preparing enoxolone |
| CN101607980A (en) * | 2009-06-15 | 2009-12-23 | 北京九草堂药物研究院有限公司 | A kind of preparation of licorice extract of bulk drug for livestock |
| CN101838303A (en) * | 2010-06-07 | 2010-09-22 | 昆明理工大学 | Preparation method of glycyrrhetinic acid |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106543261A (en) * | 2016-10-27 | 2017-03-29 | 深圳市新阳唯康科技有限公司 | A kind of enoxolone crystal-form substances and preparation method thereof |
| CN106632575A (en) * | 2016-12-20 | 2017-05-10 | 深圳市新阳唯康科技有限公司 | Novel glycyrrhetinic acid crystal form and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101461949B (en) | Berberine cyclodextrin inclusion compound, preparation thereof and preparation method | |
| CN100463916C (en) | Preparation of hemsleyadine-A and its use of preparing pharmaceutics against cancers | |
| CN102771593A (en) | Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method | |
| CN101804096B (en) | Method for extracting purified total alkaloid of strychnos nux-vomica and application thereof in pharmacy | |
| CN101313927A (en) | Southernwood total flavone, method for preparing its composition and medicine uses thereof | |
| CN102786573A (en) | Glycyrrhetinic acid crystal B substance, its preparation method, and its applications in medicines and healthcare products | |
| CN104707148A (en) | Polyethylene glycol modified glycyrrhetinic acid and curcumin compound used for resisting hepatic carcinoma, and preparation method thereof | |
| CN104513290B (en) | Triptolidenol derivative and its application | |
| CN102786518B (en) | Palmatine hydrochloride crystal B-type material and preparation method are applied with in medicine and health product | |
| CN102786417A (en) | Chlorogenic acid crystal III characterization and preparation methods, and applications of chlorogenic acid crystal III in medicines and healthcare products | |
| CN102786574A (en) | Glycyrrhetinic acid crystal A substance, its preparation method, and its applications in medicines and healthcare products | |
| CN104045679B (en) | Glycyrrhetinic acid crystal C type, its preparation method and the purposes in pharmaceutical composition or healthcare products thereof | |
| CN104016978A (en) | Palmatine hydrochloride crystal form C as well as preparation method thereof and application thereof in medicament composition or health-care product | |
| CN102976943B (en) | The alpha-crystal form material of salvianolic acid A, method for making and pharmaceutical composition and purposes | |
| CN1857400A (en) | Coated selfheal tablet and its preparing method | |
| CN101899041A (en) | A preponderant medicinal crystalline solid substance of puerarin, its preparation method and application | |
| CN102786418B (en) | Chlorogenic acid brilliant II type sign and preparation method and apply in medicine and health products | |
| CN102786519A (en) | Praziquantel crystal B substance, its preparation method and its applications in medicines and healthcare products | |
| CN102786520A (en) | Praziquantel crystal A substance, its preparation method and its applications in medicines and healthcare products | |
| CN1582970A (en) | Extraction of effective portion of gryllotalpidae for anti-cancers and its preparation | |
| CN106176987A (en) | Gentiana veitchiorum effective site and its preparation method and application | |
| CN1839926A (en) | Medicine for treating acute and chronic pharyngitis, tumour, and the rabdosia extraction method | |
| CN101633661B (en) | Process for preparing sodium cantharidinate | |
| CN103450142B (en) | Chroman compound as well as extracting method and application thereof | |
| CN102670698A (en) | Application of philippine flemingia root extract in preparation of medicines for preventing and treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121121 |